Osteopenia predicts outcomes in pancreatic cancer Study Background Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer deaths in the United States and is projected to become the second by 2030. The unfavorable prognosis of PDAC can be attributed to late diagnosis, poor metabolic status, and the resistance of cancer